Global Radioembolization Therapy Market
Global Radioembolization Therapy Market

Radioembolization Therapy Comprehensive Study by Application (Hepatocellular Carcinoma, Liver Cancer), Procedure (Transarterial Radioembolization, Selective Internal Radiation Therapy), End User (Hospital, Clinics, Ambulatory Surgical Centers) Players and Region - Global Market Outlook to 2026

Radioembolization Therapy Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Jan 2022 Edition 237 Pages 218 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is Radioembolization Therapy?
Radioembolization is a kind of brachytherapy in which 90Y-loaded microspheres are injected intra-arterially and used as inside radiation sources. It has an common sickness manipulate price of extra than 80% and is normally nicely tolerated. The fundamental issues are prompted by means of immoderate irradiation of non-target tissues, such as the liver, as a substitute than by way of the microembolic effect, even in sufferers with portal vein obstruction. All of the records for radioembolization in HCC comes from retrospective research or non-controlled potential research. However, the literature can furnish credible data, in particular after the current launch of huge sequence involving nearly seven hundred individuals. Radioembolization constantly can provide comparable survival costs to the popular of cure for intermediate and superior levels (transarterial embolization and sorafenib). In the margins of these stages, two warning signs for first-line radioembolization appear in particular appealing.

The market study is broken down, by Application (Hepatocellular Carcinoma and Liver Cancer) and major geographies with country level break-up.

The market is seeing moderate market players, by seeing huge growth in this market the key leading vendors are highly focusing towards the production technologies, efficiency enhancement and product life. There is various growth opportunity in this market which is captured by leading players via tracking the ongoing process enhancement and huge invest in market growth strategies. and Key Target Audience Analysts at AMA Research estimates that Players from United States will contribute to the maximum growth of Global Radioembolization Therapy market throughout the predicted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Eli Lilly (United States), AbbVie (United States), Amgen (United States), Pfizer (United States), AstraZeneca (United Kingdom), Johnson & Johnson (United States), Novartis (Switzerland), Merck (United States), Roche (Switzerland) and Bristol-Myers Squibb (United States) are some of the key players that are part of study coverage.

Segmentation Overview
AdvanceMarketAnalytics has segmented the market of Global Radioembolization Therapy market by Type, Application and Region.

On the basis of geography, the market of Radioembolization Therapy has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Procedure, the sub-segment i.e. Transarterial Radioembolization will boost the Radioembolization Therapy market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End User, the sub-segment i.e. Hospital will boost the Radioembolization Therapy market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

In 2021,Bristol Myers Squibb announced that the U.S. Food and Drug Administration has approved Breyanzi a CD19-directed chimeric antigen receptor T cell therapy for the treatment of adult patients with relapsed or refractory (R/R) large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B. Breyanzi is not indicated for the treatment of patients with primary central nervous system lymphoma.1Breyanzi is a CD19-directed CAR T cell therapy with a defined composition and 4-1BB costimulatory domain. Breyanzi is administered as a defined composition to reduce variability of the CD8 and CD4 component dose.


Market Trend
  • Introduction to new mobility therapy

Market Drivers
  • Rising prevalence of cancer, availability of treatment
  • Growing awareness regarding health

Opportunities
  • R&D activities and producing innovative technologies

Restraints
  • Strict regulation for the approval of radioembolization therapy

Challenges
  • Lack of skilled professionals


Key Target Audience
Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have the better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with purpose to understand company’s positioning regarding market value, volume and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders etc. and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and after getting appointee list; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey etc.

Frequently Asked Questions (FAQ):

1. What all players are profiled in the study?
The standard version of the report profiles players such as Eli Lilly (United States), AbbVie (United States), Amgen (United States), Pfizer (United States), AstraZeneca (United Kingdom), Johnson & Johnson (United States), Novartis (Switzerland), Merck (United States), Roche (Switzerland) and Bristol-Myers Squibb (United States) etc.

2. Can we have customized study for Radioembolization Therapy Market?
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.

3. What would be the Market Size of Radioembolization Therapy Market by 2026?
Analysts at AMA estimates Radioembolization Therapy Market to reach USD Million by 2026.
Report Objectives / Segmentation Covered
By Application
  • Hepatocellular Carcinoma
  • Liver Cancer
By Procedure
  • Transarterial Radioembolization
  • Selective Internal Radiation Therapy

By End User
  • Hospital
  • Clinics
  • Ambulatory Surgical Centers

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising prevalence of cancer, availability of treatment
      • 3.2.2. Growing awareness regarding health
    • 3.3. Market Challenges
      • 3.3.1. Lack of skilled professionals
    • 3.4. Market Trends
      • 3.4.1. Introduction to new mobility therapy
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Radioembolization Therapy, by Application, Procedure, End User and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Radioembolization Therapy (Value)
      • 5.2.1. Global Radioembolization Therapy by: Application (Value)
        • 5.2.1.1. Hepatocellular Carcinoma
        • 5.2.1.2. Liver Cancer
      • 5.2.2. Global Radioembolization Therapy by: Procedure (Value)
        • 5.2.2.1. Transarterial Radioembolization
        • 5.2.2.2. Selective Internal Radiation Therapy
      • 5.2.3. Global Radioembolization Therapy by: End User (Value)
        • 5.2.3.1. Hospital
        • 5.2.3.2. Clinics
        • 5.2.3.3. Ambulatory Surgical Centers
      • 5.2.4. Global Radioembolization Therapy Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Radioembolization Therapy: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Eli Lilly (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. AbbVie (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Amgen (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Pfizer (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. AstraZeneca (United Kingdom)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Johnson & Johnson (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Novartis (Switzerland)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Merck (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Roche (Switzerland)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Bristol-Myers Squibb (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Radioembolization Therapy Sale, by Application, Procedure, End User and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Radioembolization Therapy (Value)
      • 7.2.1. Global Radioembolization Therapy by: Application (Value)
        • 7.2.1.1. Hepatocellular Carcinoma
        • 7.2.1.2. Liver Cancer
      • 7.2.2. Global Radioembolization Therapy by: Procedure (Value)
        • 7.2.2.1. Transarterial Radioembolization
        • 7.2.2.2. Selective Internal Radiation Therapy
      • 7.2.3. Global Radioembolization Therapy by: End User (Value)
        • 7.2.3.1. Hospital
        • 7.2.3.2. Clinics
        • 7.2.3.3. Ambulatory Surgical Centers
      • 7.2.4. Global Radioembolization Therapy Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Radioembolization Therapy: by Application(USD Million)
  • Table 2. Radioembolization Therapy Hepatocellular Carcinoma , by Region USD Million (2015-2020)
  • Table 3. Radioembolization Therapy Liver Cancer , by Region USD Million (2015-2020)
  • Table 4. Radioembolization Therapy: by Procedure(USD Million)
  • Table 5. Radioembolization Therapy Transarterial Radioembolization , by Region USD Million (2015-2020)
  • Table 6. Radioembolization Therapy Selective Internal Radiation Therapy , by Region USD Million (2015-2020)
  • Table 7. Radioembolization Therapy: by End User(USD Million)
  • Table 8. Radioembolization Therapy Hospital , by Region USD Million (2015-2020)
  • Table 9. Radioembolization Therapy Clinics , by Region USD Million (2015-2020)
  • Table 10. Radioembolization Therapy Ambulatory Surgical Centers , by Region USD Million (2015-2020)
  • Table 11. South America Radioembolization Therapy, by Country USD Million (2015-2020)
  • Table 12. South America Radioembolization Therapy, by Application USD Million (2015-2020)
  • Table 13. South America Radioembolization Therapy, by Procedure USD Million (2015-2020)
  • Table 14. South America Radioembolization Therapy, by End User USD Million (2015-2020)
  • Table 15. Brazil Radioembolization Therapy, by Application USD Million (2015-2020)
  • Table 16. Brazil Radioembolization Therapy, by Procedure USD Million (2015-2020)
  • Table 17. Brazil Radioembolization Therapy, by End User USD Million (2015-2020)
  • Table 18. Argentina Radioembolization Therapy, by Application USD Million (2015-2020)
  • Table 19. Argentina Radioembolization Therapy, by Procedure USD Million (2015-2020)
  • Table 20. Argentina Radioembolization Therapy, by End User USD Million (2015-2020)
  • Table 21. Rest of South America Radioembolization Therapy, by Application USD Million (2015-2020)
  • Table 22. Rest of South America Radioembolization Therapy, by Procedure USD Million (2015-2020)
  • Table 23. Rest of South America Radioembolization Therapy, by End User USD Million (2015-2020)
  • Table 24. Asia Pacific Radioembolization Therapy, by Country USD Million (2015-2020)
  • Table 25. Asia Pacific Radioembolization Therapy, by Application USD Million (2015-2020)
  • Table 26. Asia Pacific Radioembolization Therapy, by Procedure USD Million (2015-2020)
  • Table 27. Asia Pacific Radioembolization Therapy, by End User USD Million (2015-2020)
  • Table 28. China Radioembolization Therapy, by Application USD Million (2015-2020)
  • Table 29. China Radioembolization Therapy, by Procedure USD Million (2015-2020)
  • Table 30. China Radioembolization Therapy, by End User USD Million (2015-2020)
  • Table 31. Japan Radioembolization Therapy, by Application USD Million (2015-2020)
  • Table 32. Japan Radioembolization Therapy, by Procedure USD Million (2015-2020)
  • Table 33. Japan Radioembolization Therapy, by End User USD Million (2015-2020)
  • Table 34. India Radioembolization Therapy, by Application USD Million (2015-2020)
  • Table 35. India Radioembolization Therapy, by Procedure USD Million (2015-2020)
  • Table 36. India Radioembolization Therapy, by End User USD Million (2015-2020)
  • Table 37. South Korea Radioembolization Therapy, by Application USD Million (2015-2020)
  • Table 38. South Korea Radioembolization Therapy, by Procedure USD Million (2015-2020)
  • Table 39. South Korea Radioembolization Therapy, by End User USD Million (2015-2020)
  • Table 40. Taiwan Radioembolization Therapy, by Application USD Million (2015-2020)
  • Table 41. Taiwan Radioembolization Therapy, by Procedure USD Million (2015-2020)
  • Table 42. Taiwan Radioembolization Therapy, by End User USD Million (2015-2020)
  • Table 43. Australia Radioembolization Therapy, by Application USD Million (2015-2020)
  • Table 44. Australia Radioembolization Therapy, by Procedure USD Million (2015-2020)
  • Table 45. Australia Radioembolization Therapy, by End User USD Million (2015-2020)
  • Table 46. Rest of Asia-Pacific Radioembolization Therapy, by Application USD Million (2015-2020)
  • Table 47. Rest of Asia-Pacific Radioembolization Therapy, by Procedure USD Million (2015-2020)
  • Table 48. Rest of Asia-Pacific Radioembolization Therapy, by End User USD Million (2015-2020)
  • Table 49. Europe Radioembolization Therapy, by Country USD Million (2015-2020)
  • Table 50. Europe Radioembolization Therapy, by Application USD Million (2015-2020)
  • Table 51. Europe Radioembolization Therapy, by Procedure USD Million (2015-2020)
  • Table 52. Europe Radioembolization Therapy, by End User USD Million (2015-2020)
  • Table 53. Germany Radioembolization Therapy, by Application USD Million (2015-2020)
  • Table 54. Germany Radioembolization Therapy, by Procedure USD Million (2015-2020)
  • Table 55. Germany Radioembolization Therapy, by End User USD Million (2015-2020)
  • Table 56. France Radioembolization Therapy, by Application USD Million (2015-2020)
  • Table 57. France Radioembolization Therapy, by Procedure USD Million (2015-2020)
  • Table 58. France Radioembolization Therapy, by End User USD Million (2015-2020)
  • Table 59. Italy Radioembolization Therapy, by Application USD Million (2015-2020)
  • Table 60. Italy Radioembolization Therapy, by Procedure USD Million (2015-2020)
  • Table 61. Italy Radioembolization Therapy, by End User USD Million (2015-2020)
  • Table 62. United Kingdom Radioembolization Therapy, by Application USD Million (2015-2020)
  • Table 63. United Kingdom Radioembolization Therapy, by Procedure USD Million (2015-2020)
  • Table 64. United Kingdom Radioembolization Therapy, by End User USD Million (2015-2020)
  • Table 65. Netherlands Radioembolization Therapy, by Application USD Million (2015-2020)
  • Table 66. Netherlands Radioembolization Therapy, by Procedure USD Million (2015-2020)
  • Table 67. Netherlands Radioembolization Therapy, by End User USD Million (2015-2020)
  • Table 68. Rest of Europe Radioembolization Therapy, by Application USD Million (2015-2020)
  • Table 69. Rest of Europe Radioembolization Therapy, by Procedure USD Million (2015-2020)
  • Table 70. Rest of Europe Radioembolization Therapy, by End User USD Million (2015-2020)
  • Table 71. MEA Radioembolization Therapy, by Country USD Million (2015-2020)
  • Table 72. MEA Radioembolization Therapy, by Application USD Million (2015-2020)
  • Table 73. MEA Radioembolization Therapy, by Procedure USD Million (2015-2020)
  • Table 74. MEA Radioembolization Therapy, by End User USD Million (2015-2020)
  • Table 75. Middle East Radioembolization Therapy, by Application USD Million (2015-2020)
  • Table 76. Middle East Radioembolization Therapy, by Procedure USD Million (2015-2020)
  • Table 77. Middle East Radioembolization Therapy, by End User USD Million (2015-2020)
  • Table 78. Africa Radioembolization Therapy, by Application USD Million (2015-2020)
  • Table 79. Africa Radioembolization Therapy, by Procedure USD Million (2015-2020)
  • Table 80. Africa Radioembolization Therapy, by End User USD Million (2015-2020)
  • Table 81. North America Radioembolization Therapy, by Country USD Million (2015-2020)
  • Table 82. North America Radioembolization Therapy, by Application USD Million (2015-2020)
  • Table 83. North America Radioembolization Therapy, by Procedure USD Million (2015-2020)
  • Table 84. North America Radioembolization Therapy, by End User USD Million (2015-2020)
  • Table 85. United States Radioembolization Therapy, by Application USD Million (2015-2020)
  • Table 86. United States Radioembolization Therapy, by Procedure USD Million (2015-2020)
  • Table 87. United States Radioembolization Therapy, by End User USD Million (2015-2020)
  • Table 88. Canada Radioembolization Therapy, by Application USD Million (2015-2020)
  • Table 89. Canada Radioembolization Therapy, by Procedure USD Million (2015-2020)
  • Table 90. Canada Radioembolization Therapy, by End User USD Million (2015-2020)
  • Table 91. Mexico Radioembolization Therapy, by Application USD Million (2015-2020)
  • Table 92. Mexico Radioembolization Therapy, by Procedure USD Million (2015-2020)
  • Table 93. Mexico Radioembolization Therapy, by End User USD Million (2015-2020)
  • Table 94. Company Basic Information, Sales Area and Its Competitors
  • Table 95. Company Basic Information, Sales Area and Its Competitors
  • Table 96. Company Basic Information, Sales Area and Its Competitors
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Radioembolization Therapy: by Application(USD Million)
  • Table 105. Radioembolization Therapy Hepatocellular Carcinoma , by Region USD Million (2021-2026)
  • Table 106. Radioembolization Therapy Liver Cancer , by Region USD Million (2021-2026)
  • Table 107. Radioembolization Therapy: by Procedure(USD Million)
  • Table 108. Radioembolization Therapy Transarterial Radioembolization , by Region USD Million (2021-2026)
  • Table 109. Radioembolization Therapy Selective Internal Radiation Therapy , by Region USD Million (2021-2026)
  • Table 110. Radioembolization Therapy: by End User(USD Million)
  • Table 111. Radioembolization Therapy Hospital , by Region USD Million (2021-2026)
  • Table 112. Radioembolization Therapy Clinics , by Region USD Million (2021-2026)
  • Table 113. Radioembolization Therapy Ambulatory Surgical Centers , by Region USD Million (2021-2026)
  • Table 114. South America Radioembolization Therapy, by Country USD Million (2021-2026)
  • Table 115. South America Radioembolization Therapy, by Application USD Million (2021-2026)
  • Table 116. South America Radioembolization Therapy, by Procedure USD Million (2021-2026)
  • Table 117. South America Radioembolization Therapy, by End User USD Million (2021-2026)
  • Table 118. Brazil Radioembolization Therapy, by Application USD Million (2021-2026)
  • Table 119. Brazil Radioembolization Therapy, by Procedure USD Million (2021-2026)
  • Table 120. Brazil Radioembolization Therapy, by End User USD Million (2021-2026)
  • Table 121. Argentina Radioembolization Therapy, by Application USD Million (2021-2026)
  • Table 122. Argentina Radioembolization Therapy, by Procedure USD Million (2021-2026)
  • Table 123. Argentina Radioembolization Therapy, by End User USD Million (2021-2026)
  • Table 124. Rest of South America Radioembolization Therapy, by Application USD Million (2021-2026)
  • Table 125. Rest of South America Radioembolization Therapy, by Procedure USD Million (2021-2026)
  • Table 126. Rest of South America Radioembolization Therapy, by End User USD Million (2021-2026)
  • Table 127. Asia Pacific Radioembolization Therapy, by Country USD Million (2021-2026)
  • Table 128. Asia Pacific Radioembolization Therapy, by Application USD Million (2021-2026)
  • Table 129. Asia Pacific Radioembolization Therapy, by Procedure USD Million (2021-2026)
  • Table 130. Asia Pacific Radioembolization Therapy, by End User USD Million (2021-2026)
  • Table 131. China Radioembolization Therapy, by Application USD Million (2021-2026)
  • Table 132. China Radioembolization Therapy, by Procedure USD Million (2021-2026)
  • Table 133. China Radioembolization Therapy, by End User USD Million (2021-2026)
  • Table 134. Japan Radioembolization Therapy, by Application USD Million (2021-2026)
  • Table 135. Japan Radioembolization Therapy, by Procedure USD Million (2021-2026)
  • Table 136. Japan Radioembolization Therapy, by End User USD Million (2021-2026)
  • Table 137. India Radioembolization Therapy, by Application USD Million (2021-2026)
  • Table 138. India Radioembolization Therapy, by Procedure USD Million (2021-2026)
  • Table 139. India Radioembolization Therapy, by End User USD Million (2021-2026)
  • Table 140. South Korea Radioembolization Therapy, by Application USD Million (2021-2026)
  • Table 141. South Korea Radioembolization Therapy, by Procedure USD Million (2021-2026)
  • Table 142. South Korea Radioembolization Therapy, by End User USD Million (2021-2026)
  • Table 143. Taiwan Radioembolization Therapy, by Application USD Million (2021-2026)
  • Table 144. Taiwan Radioembolization Therapy, by Procedure USD Million (2021-2026)
  • Table 145. Taiwan Radioembolization Therapy, by End User USD Million (2021-2026)
  • Table 146. Australia Radioembolization Therapy, by Application USD Million (2021-2026)
  • Table 147. Australia Radioembolization Therapy, by Procedure USD Million (2021-2026)
  • Table 148. Australia Radioembolization Therapy, by End User USD Million (2021-2026)
  • Table 149. Rest of Asia-Pacific Radioembolization Therapy, by Application USD Million (2021-2026)
  • Table 150. Rest of Asia-Pacific Radioembolization Therapy, by Procedure USD Million (2021-2026)
  • Table 151. Rest of Asia-Pacific Radioembolization Therapy, by End User USD Million (2021-2026)
  • Table 152. Europe Radioembolization Therapy, by Country USD Million (2021-2026)
  • Table 153. Europe Radioembolization Therapy, by Application USD Million (2021-2026)
  • Table 154. Europe Radioembolization Therapy, by Procedure USD Million (2021-2026)
  • Table 155. Europe Radioembolization Therapy, by End User USD Million (2021-2026)
  • Table 156. Germany Radioembolization Therapy, by Application USD Million (2021-2026)
  • Table 157. Germany Radioembolization Therapy, by Procedure USD Million (2021-2026)
  • Table 158. Germany Radioembolization Therapy, by End User USD Million (2021-2026)
  • Table 159. France Radioembolization Therapy, by Application USD Million (2021-2026)
  • Table 160. France Radioembolization Therapy, by Procedure USD Million (2021-2026)
  • Table 161. France Radioembolization Therapy, by End User USD Million (2021-2026)
  • Table 162. Italy Radioembolization Therapy, by Application USD Million (2021-2026)
  • Table 163. Italy Radioembolization Therapy, by Procedure USD Million (2021-2026)
  • Table 164. Italy Radioembolization Therapy, by End User USD Million (2021-2026)
  • Table 165. United Kingdom Radioembolization Therapy, by Application USD Million (2021-2026)
  • Table 166. United Kingdom Radioembolization Therapy, by Procedure USD Million (2021-2026)
  • Table 167. United Kingdom Radioembolization Therapy, by End User USD Million (2021-2026)
  • Table 168. Netherlands Radioembolization Therapy, by Application USD Million (2021-2026)
  • Table 169. Netherlands Radioembolization Therapy, by Procedure USD Million (2021-2026)
  • Table 170. Netherlands Radioembolization Therapy, by End User USD Million (2021-2026)
  • Table 171. Rest of Europe Radioembolization Therapy, by Application USD Million (2021-2026)
  • Table 172. Rest of Europe Radioembolization Therapy, by Procedure USD Million (2021-2026)
  • Table 173. Rest of Europe Radioembolization Therapy, by End User USD Million (2021-2026)
  • Table 174. MEA Radioembolization Therapy, by Country USD Million (2021-2026)
  • Table 175. MEA Radioembolization Therapy, by Application USD Million (2021-2026)
  • Table 176. MEA Radioembolization Therapy, by Procedure USD Million (2021-2026)
  • Table 177. MEA Radioembolization Therapy, by End User USD Million (2021-2026)
  • Table 178. Middle East Radioembolization Therapy, by Application USD Million (2021-2026)
  • Table 179. Middle East Radioembolization Therapy, by Procedure USD Million (2021-2026)
  • Table 180. Middle East Radioembolization Therapy, by End User USD Million (2021-2026)
  • Table 181. Africa Radioembolization Therapy, by Application USD Million (2021-2026)
  • Table 182. Africa Radioembolization Therapy, by Procedure USD Million (2021-2026)
  • Table 183. Africa Radioembolization Therapy, by End User USD Million (2021-2026)
  • Table 184. North America Radioembolization Therapy, by Country USD Million (2021-2026)
  • Table 185. North America Radioembolization Therapy, by Application USD Million (2021-2026)
  • Table 186. North America Radioembolization Therapy, by Procedure USD Million (2021-2026)
  • Table 187. North America Radioembolization Therapy, by End User USD Million (2021-2026)
  • Table 188. United States Radioembolization Therapy, by Application USD Million (2021-2026)
  • Table 189. United States Radioembolization Therapy, by Procedure USD Million (2021-2026)
  • Table 190. United States Radioembolization Therapy, by End User USD Million (2021-2026)
  • Table 191. Canada Radioembolization Therapy, by Application USD Million (2021-2026)
  • Table 192. Canada Radioembolization Therapy, by Procedure USD Million (2021-2026)
  • Table 193. Canada Radioembolization Therapy, by End User USD Million (2021-2026)
  • Table 194. Mexico Radioembolization Therapy, by Application USD Million (2021-2026)
  • Table 195. Mexico Radioembolization Therapy, by Procedure USD Million (2021-2026)
  • Table 196. Mexico Radioembolization Therapy, by End User USD Million (2021-2026)
  • Table 197. Research Programs/Design for This Report
  • Table 198. Key Data Information from Secondary Sources
  • Table 199. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Radioembolization Therapy: by Application USD Million (2015-2020)
  • Figure 5. Global Radioembolization Therapy: by Procedure USD Million (2015-2020)
  • Figure 6. Global Radioembolization Therapy: by End User USD Million (2015-2020)
  • Figure 7. South America Radioembolization Therapy Share (%), by Country
  • Figure 8. Asia Pacific Radioembolization Therapy Share (%), by Country
  • Figure 9. Europe Radioembolization Therapy Share (%), by Country
  • Figure 10. MEA Radioembolization Therapy Share (%), by Country
  • Figure 11. North America Radioembolization Therapy Share (%), by Country
  • Figure 12. Global Radioembolization Therapy share by Players 2020 (%)
  • Figure 13. Global Radioembolization Therapy share by Players (Top 3) 2020(%)
  • Figure 14. Global Radioembolization Therapy share by Players (Top 5) 2020(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Eli Lilly (United States) Revenue, Net Income and Gross profit
  • Figure 17. Eli Lilly (United States) Revenue: by Geography 2020
  • Figure 18. AbbVie (United States) Revenue, Net Income and Gross profit
  • Figure 19. AbbVie (United States) Revenue: by Geography 2020
  • Figure 20. Amgen (United States) Revenue, Net Income and Gross profit
  • Figure 21. Amgen (United States) Revenue: by Geography 2020
  • Figure 22. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 23. Pfizer (United States) Revenue: by Geography 2020
  • Figure 24. AstraZeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 25. AstraZeneca (United Kingdom) Revenue: by Geography 2020
  • Figure 26. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 27. Johnson & Johnson (United States) Revenue: by Geography 2020
  • Figure 28. Novartis (Switzerland) Revenue, Net Income and Gross profit
  • Figure 29. Novartis (Switzerland) Revenue: by Geography 2020
  • Figure 30. Merck (United States) Revenue, Net Income and Gross profit
  • Figure 31. Merck (United States) Revenue: by Geography 2020
  • Figure 32. Roche (Switzerland) Revenue, Net Income and Gross profit
  • Figure 33. Roche (Switzerland) Revenue: by Geography 2020
  • Figure 34. Bristol-Myers Squibb (United States) Revenue, Net Income and Gross profit
  • Figure 35. Bristol-Myers Squibb (United States) Revenue: by Geography 2020
  • Figure 36. Global Radioembolization Therapy: by Application USD Million (2021-2026)
  • Figure 37. Global Radioembolization Therapy: by Procedure USD Million (2021-2026)
  • Figure 38. Global Radioembolization Therapy: by End User USD Million (2021-2026)
  • Figure 39. South America Radioembolization Therapy Share (%), by Country
  • Figure 40. Asia Pacific Radioembolization Therapy Share (%), by Country
  • Figure 41. Europe Radioembolization Therapy Share (%), by Country
  • Figure 42. MEA Radioembolization Therapy Share (%), by Country
  • Figure 43. North America Radioembolization Therapy Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Eli Lilly (United States)
  • AbbVie (United States)
  • Amgen (United States)
  • Pfizer (United States)
  • AstraZeneca (United Kingdom)
  • Johnson & Johnson (United States)
  • Novartis (Switzerland)
  • Merck (United States)
  • Roche (Switzerland)
  • Bristol-Myers Squibb (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation